The role of revascularisation in the management of non-ST elevation acute coronary syndromes: Who should you refer?

Clinical Medicine

Volumn 4, Issue 1, 2004, Pages 32-35

  Archbold, R Andrew ^a   Curzen, Nicholas P ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT REFERRAL; REVIEW; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 1342311902     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.4-1-32     Document Type: Review

References (18)

1. Collinson J, Flather MD, Fox KA, Findlay I et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000;21:1450-7.
2. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Review. Circulation 1995;92: 657-71.
3. Archbold RA, Curzen NP. Issues relating to clopidogrel use in hospital practice. Br J Cardiol 2002;9(Suppl 8):S13-19.
4. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89: 1545-56.
5. Anderson HV, Cannon CP, Stone PH, Williams DO et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643-50.
6. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
7. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multi-centre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-15.
8. Lagerqvist B, Husted S, Kontny F, Nashund U et al; Fast Revascularization during InStability in Coronary Artery Disease-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002;40:1902-14.
9. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R et al; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis In Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
10. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC et al; Randomized Intervention Trial of unstable Angina (RITA) Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002; 360:743-51.
11. Miller C, Lipscomb K, Curzen N. Are district general hospital patients with unstable angina at a disadvantage? Postgrad Med J 2003;79:93-8.
12. Lindahl B, Diderholm E, Lagerqvist B, Venge P et al; FRISC II (Fast Revascularization during InStability in CAD) Investigators. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979-86.
13. Smith E, Fath-Ordoubadi F, Curzen N. Unstable angina: the case for selective aggression. Br J Cardiol 2002;9:251-4.
14. Toss H, Lindahl B, Siegbahn A, Wallenstein L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group (Fragmin during Instability in Coronary Artery Disease). Circulation 1997;96:4204-10.
15. Lindahl B, Toss H, Siegbahn A, Venge R Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-47.
16. James SK, Armstrong P, Barnathan E, Califf R et al; GUSTO-IV-ACS Investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003;41:916-24.
17. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
18. Braunwald E, Antman EM, Beasley JW, Califf RM et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106:1893-1900.